NASDAQ: EKSOEkso Bionics Holdings Inc Stock
$0.42-0.04 (-8.7%)
Updated Mar 14, 2025
EKSO Price
$0.42
Fair Value Price
N/A
Market Cap
$10.53M
52 Week Low
$0.34
52 Week High
$1.53
P/E
-0.76x
P/B
0.83x
P/S
0.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$17.93M
Earnings
-$11.33M
Gross Margin
53.1%
Operating Margin
-61.71%
Profit Margin
-63.2%
Debt to Equity
1.1
Operating Cash Flow
-$10M
Beta
0.69
Next Earnings
Apr 28, 2025
Ex-Dividend
N/A
Next Dividend
N/A
EKSO Overview
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EKSO's potential to beat the market
- EKSO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important EKSO news, forecast changes, insider trades & much more!
EKSO News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EKSO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EKSO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EKSO is good value based on its book value relative to its share price (0.83x), compared to the US Medical Instruments & Supplies industry average (3.69x)
P/B vs Industry Valuation
EKSO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EKSO due diligence checks available for Premium users.
Valuation
EKSO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.76x
Industry
38.15x
Market
3,446.61x
EKSO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.83x
Industry
3.69x
EKSO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EKSO's financial health
Profit margin
Revenue
$5.1M
Net Income
-$3.4M
Profit Margin
-67.1%
EKSO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
EKSO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$26.7M
Liabilities
$13.9M
Debt to equity
1.1
EKSO's short-term assets ($18.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EKSO's short-term assets ($18.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EKSO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EKSO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.4M
Investing
-$21.0k
Financing
-$314.0k
EKSO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EKSO vs Medical Stocks
Ekso Bionics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.